Harmony Biosciences Eyes Growth Beyond Wakix in 2025
Feb 26, 2025
Harmony Biosciences reported its Q4 and full-year earnings yesterday. Annual sales grew 23%, an impressive figure for a single orphan drug with a single indication (Wakix for narcolepsy). Management guided for approximately 18% growth in 2025 and expects this indication alone to surpass $1 billion in annual sales. The company’s long-term potential will become clearer this year, as its Phase 3 trial for ZYN002 is set to report initial data in Q3. ZYN002 was acquired through Harmony’s 2023 purchase of Zynerba, targeting Fragile X which represents a similar patient population to narcolepsy, with no currently approved treatments. A positive result could push Harmony’s stock closer to my fair value estimate of $73.
Follow @GreenDotStocks
Information contained on this website represents only the opinions of the author and should not be used as the sole basis for investing decisions. By using this site, you agree to all statements in the Site Policy.
Watch List
| APPF | 4.30% |
| CMG | 40.33% |
| PSTG | -1.39% |
| WDAY | -5.41% |
| VEEV | 19.23% |
| INTU | 20.20% |
| RDDT | 16.57% |
| NTNX | 27.22% |
| CRWD | 95.83% |
| SE | 32.72% |
| SNOW | 13.92% |
vs. Fair Value Estimates
Buy List
| PINS | -38.24% |
| SEMR | -33.68% |
| TSM | -40.25% |
| ZETA | -27.44% |
| GOOG | -50.34% |
| NYAX | -30.24% |
| MSFT | -28.00% |
| FLYW | -39.29% |
| HRMY | -59.63% |
| YOU | -39.80% |
| ABNB | -31.51% |
| ADBE | -41.68% |
vs. Fair Value Estimates
Hold List
| ASML | -23.91% |
| VTEX | -13.76% |
| ODD | -6.91% |
| ASR | -24.09% |
| CELH | 39.84% |
| TOST | 18.60% |
| CPNG | -11.81% |
| HIMS | -5.43% |
| PAYC | -18.56% |
| MNDY | 21.64% |
| GLBE | -21.93% |
| ZS | 38.75% |
| V | -4.82% |
| ADSK | 1.57% |
| NOW | 15.34% |
| MELI | -19.68% |
| FTNT | 1.73% |
| TEAM | 0.14% |
vs. Fair Value Estimates